乐德奇拜单抗(Rademikibart) - 药物靶点：IL-4Rα_在研适应症：哮喘，嗜酸性粒细胞性哮喘，中度特应性皮炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

CBP 201、CBP-201、SIM0718

靶点

IL-4Rα

作用方式

抑制剂

作用机制

IL-4Rα抑制剂(白细胞介素-4受体α亚基抑制剂)

治疗领域

免疫系统疾病遗传病与畸形血液及淋巴系统疾病+ [3]

在研适应症

哮喘嗜酸性粒细胞性哮喘中度特应性皮炎+ [8]

非在研适应症

原研机构

在研机构

非在研机构-

权益机构

苏州康乃德生物医药有限公司

先声药业有限公司

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 630309575L

来源: *****

Sequence Code 630309576H

来源: *****

关联

15

项与乐德奇拜单抗相关的临床试验

NCT06940154

/ Recruiting临床2期

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation

开始日期2025-05-01

申办/合作机构

苏州康乃德生物医药有限公司

NCT06940141

/ Recruiting临床2期

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Adult and Adolescent Participants With Asthma and Type 2 Inflammation

This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation

开始日期2025-05-01

申办/合作机构

苏州康乃德生物医药有限公司

NCT06701149

/ Not yet recruiting临床1期

A Randomized, Open-label, Single-dose, Parallel Group Study to Compare the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China

A study to compare the pharmacokinetics, safety and immunogenicity of SIM0718 injection in healthy adult subjects in China

开始日期2024-11-28

申办/合作机构

先聲藥業集團有限公司

100 项与乐德奇拜单抗相关的临床结果

登录后查看更多信息

100 项与乐德奇拜单抗相关的转化医学

登录后查看更多信息

100 项与乐德奇拜单抗相关的专利（医药）

登录后查看更多信息

6

项与乐德奇拜单抗相关的文献（医药）

2025-05-01·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Rademikibart Treatment for Moderate-to-Severe Uncontrolled Asthma: A Phase 2B Randomized Clinical Trial

Article

作者: Guo, Jiawang ; Adivikolanu, Radha ; Yun, Jili ; Wang, Junying ; Longphre, Malinda ; Kerwin, Edward ; Collazo, Raúl ; Su, Nan ; Yang, Ting ; Pan, Wuban ; Wei, Zheng

RATIONALE:

Rademikibart (formerly CBP-201) is an IL-4Rα-targeting antibody.

OBJECTIVES:

To evaluate rademikibart in adults with moderate-to-severe, persistent, uncontrolled asthma.

METHODS:

In this global phase 2b trial (NCT04773678), 322 patients were randomized 1:1:1 to two rademikibart groups (150 mg or 300 mg every other week, following a 600 mg loading dose) or placebo, administered subcutaneously, for 24 weeks.

MEASUREMENTS AND MAIN RESULTS:

Prebronchodilator (trough) forced expiratory volume in the first second of expiration (FEV₁) at Week 12 (primary endpoint) improved with rademikibart 150 mg and 300 mg: least squares mean changes (95% CI), above placebo, were +140 mL (+44-236 mL; p=0.005) and +189 mL (+92-286 mL; p<0.001), respectively. Prebronchodilator trough FEV₁ improvements occurred rapidly during Week 1, were sustained through Week 24, and greatest in patients with high baseline blood eosinophils (patients with ≥300 eosinophils/mL experienced placebo-adjusted FEV₁ improvement at Week 24 of +420 mL [95% CI, +239-600 mL] in the 300 mg group). Rapid and sustained statistically significant improvements were also observed in percent predicted FEV₁ and Asthma Control Questionnaire score across 24 weeks. Through Week 24, proportions of patients with ≥1 exacerbation were 7.5% (150 mg) and 9.3% (300 mg) vs 16.7% (placebo). 88% of patients completed treatment. Treatment-emergent adverse events (TEAEs) were generally similar to placebo, and no eosinophilia was observed. Injection site reactions were mostly mild. The most common TEAEs (10-12% of patients) were cough, COVID-19, and dyspnea.

CONCLUSIONS:

Rapid and sustained improvements in lung function and asthma control were gained across 24 weeks of rademikibart therapy. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). Clinical trial registration available at www.

CLINICALTRIALS:

gov, ID: NCT04773678.

2024-07-02·Expert opinion on emerging drugs

Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials

Review

作者: Su, Malcolm ; Obed, Ogechi ; Chong, Albert C ; Ong, Peck Y

INTRODUCTION:

Atopic dermatitis (AD) is an inflammatory skin condition that affects millions of pediatric and adult patients with well-studied impact on morbidity and quality of life. Management occurs in a stepwise fashion beginning with preventative measures before immunomodulators are introduced. However, challenges remain in treatment of moderate-to-severe atopic dermatitis that is refractory to first- and second-line treatments and there are only few topical anti-inflammatory options, especially for pediatric patients.

AREAS COVERED:

New medications are required to address these gaps as lesions may persist despite treatment or patients may discontinue treatment due to actual or anticipated adverse effects of mainstay medications. Emerging research into the pathophysiology of AD and the immune system at large has provided opportunities for novel interventions aimed at stopping AD mechanisms at new checkpoints. Clinical trials for 36 agents currently in phase 2 or phase 3 are evaluated with particular focus on the studies for, B244, CBP-201, tapinarof, lebrikizumab, nemolizumab, amlitelimab, and rocatinlimab as they explore novel pathways and have some of the most promising results.

EXPERT OPINION:

These clinical trials contribute to the evolution of AD treatment toward greater precision based on salient pathways with a particular focus on moderate-to-severe AD to enhance efficacy and minimize adverse effects.

2024-04-01·The Journal of allergy and clinical immunology

Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)

Article

作者: Pan, Wubin ; Ho, Selwyn ; Song, Jing ; Silverberg, Jonathan I ; Strober, Bruce ; Wei, Zheng ; Li, Pauline ; Guo, Jiawang ; Yun, Jang ; Xu, Jinhua ; Simpson, Eric L ; Guttman-Yassky, Emma ; Collazo, Raúl ; Longphre, Malinda ; Williams, Belinda ; Feinstein, Brian

BACKGROUND:

Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha-targeting antibody.

OBJECTIVE:

We sought to evaluate rademikibart in adults with moderate to severe atopic dermatitis.

METHODS:

A total of 226 patients were randomized, double-blind, to subcutaneous rademikibart (300 mg every 2 weeks [Q2W], 150 mg Q2W, 300 mg every 4 weeks [Q4W]; plus 600-mg loading dose) or placebo. Randomization began in July 2020. The trial was completed in October 2021.

RESULTS:

The WW001 phase 2 trial achieved its primary end point: significant percent reduction from baseline in least-squares mean Eczema Area Severity Index (EASI) to week 16 with rademikibart 300 mg Q2W (-63.0%; P = .0007), 150 mg Q2W (-57.6%; P = .0067), 300 mg Q4W (-63.5%; P = .0004) versus placebo (-39.7%). EASI scores decreased significantly with 300 mg Q2W and Q4W at the earliest assessment (week 2), with no evidence of plateauing by week 16. Significant improvements were also observed in secondary end points, including pruritus. Across the primary and secondary end points, efficacy tended to be comparable with 300 mg Q2W and Q4W dosing. Rademikibart and placebo had similar, low incidence of treatment-emergent adverse events (TEAEs) (48% vs 54%), serious TEAEs (1.8% vs 3.6%), TEAEs leading to treatment discontinuation (1.2% vs 1.8%), conjunctivitis of unspecified cause (2.9% vs 0%), herpes (0.6% vs 1.8%), and injection-site reactions (1.8% vs 1.8%). Although no discontinuations were attributed to coronavirus disease 2019, pandemic-related restrictions likely had an impact on trial conduct.

CONCLUSIONS:

Rademikibart was efficacious and well tolerated at Q2W and Q4W intervals. Q4W dosing is a more convenient frequency than approved for current therapies.

126

项与乐德奇拜单抗相关的新闻（医药）

2025-06-13

·PipelineReview

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26 – SAN DIEGO, CA, USA I June 13, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the presentation of clinical data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. “The data being presented today at EAACI continues to demonstrate the potential of rademikibart to deliver best-in-class efficacy for asthma patients,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “Building on the previously reported data from our Phase 2b asthma study, these analyses highlight rademikibart’s capability to not only rapidly deliver improvements in lung function, but also significantly reduce annualized asthma exacerbation rates, particularly in those with high eosinophil and fractional exhaled nitric oxide or FeNO counts, key markers of type 2 inflammation. We believe these findings continue to bolster support for our rapid Phase 2 clinical development plan and we look forward to reporting topline data from our parallel Seabreeze STAT studies in the first half of 2026.” Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma Abstract Number: 001678 Presenter: Rekha Chaudhuri, M.D. Session Title: Clinical Trials on Airways Diseases Date and Time: Friday, June 13 th from 3:00 p.m. – 4:30 p.m. BST Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma Abstract Number: 001671 Presenter: Rekha Chaudhuri, M.D. Session Title: Clinical Trials on Airways Diseases Date and Time: Friday, June 13 th from 3:00 p.m. – 4:30 p.m. BST The presentations are available on Connect’s website under the presentations and publications section . About Connect Biopharma and Rademikibart Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV 1 ), observed within one week—and in most cases, within 24 hours via home spirometry. For more information visit www.connectbiopharm.com . SOURCE: Connect Biopharma

临床2期临床结果免疫疗法

2025-06-03

·GlobeNewswire-Health Care

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The presentation details are as follows: Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 AsthmaAbstract Number: 001671Presenter: Rekha Chaudhuri, M.D.Session Title: Clinical Trials on Airways DiseasesDate and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 AsthmaAbstract Number: 001678Presenter: Rekha Chaudhuri, M.D.Session Title: Clinical Trials on Airways DiseasesDate and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST Following the presentations, each presentation will be available on Connect’s website under the presentations and publications section. About Connect Biopharma and RademikibartConnect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week—and in most cases, within 24 hours via home spirometry. For more information visit www.connectbiopharm.com. Investor Relations Contact: Alex Lobo Precision AQ Alex.lobo@precisionaq.com (212) 698-8802 Media Contact: Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, LLCIgnacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 or (646) 942-5604

临床2期免疫疗法

2025-05-21

·PipelineReview

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated structural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα ) inhibition compared to dupilumab providing a molecular basis for the differentiated efficacy and safety observed with rademikibart presented at this meeting – SAN DIEGO, CA, USA I May 20, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced clinical and preclinical data supporting rademikibart, the Company’s next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, which was presented at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 18-21, 2025, in San Francisco. “We are pleased to share new clinical and preclinical data highlighting rademikibart’s potential as a best-in-class treatment for patients with asthma or COPD experiencing an acute exacerbation,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “The new analyses from our previously completed Phase 2b study not only demonstrate rademikibart’s rapid onset of action and significant improvement in lung function, but also further differentiate its safety profile, overcoming limitations of existing IL-4Rα inhibitors on the market. Taken together, these data reinforce our confidence in our clinical development plan and provide strong commercial rationale for rademikibart as a potentially superior next-generation IL-4Rα inhibitor.” Title: Rapid Improvement in Lung Function Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma Title: Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients with Moderate-to-Severe Asthma Title: Effect of Rademikibart on Blood Eosinophil Counts in Patients with Asthma: Is There an IL-4Rα Class Effect? Title: Optimized Second-generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex The poster presentations will be available on Connect’s website under the Presentations and Publications section . About Connect Biopharma and Rademikibart Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV 1 ), observed within one week—and in most cases, within 24 hours via home spirometry. For more information visit www.connectbiopharm.com . SOURCE: Connect Biopharma

临床2期临床结果

100 项与乐德奇拜单抗相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	中国	先聲藥業集團有限公司	2024-07-23
嗜酸性粒细胞性哮喘	临床3期	中国	先聲藥業集團有限公司	2024-07-23
重度哮喘	临床3期	中国	苏州康乃德生物医药有限公司	2024-07-01
中度特应性皮炎	临床3期	-	苏州康乃德生物医药有限公司	2022-12-01
重度特应性皮炎	临床3期	-	苏州康乃德生物医药有限公司	2022-12-01
慢性哮喘	临床3期	中国	苏州康乃德生物医药有限公司	-
急性哮喘	临床2期	美国	苏州康乃德生物医药有限公司	2025-05-01
慢性阻塞性肺疾病	临床2期	美国	苏州康乃德生物医药有限公司	2025-05-01
特应性皮炎	临床2期	中国	先聲藥業集團有限公司	2023-11-23
慢性鼻窦炎伴鼻息肉	临床2期	美国	苏州康乃德生物医药有限公司	2021-06-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04773678 (Phase 2b trial, ATS2025)	临床2期	哮喘 blood eosinophil count	322	Rademikibart 600 mg loading dose	鏇繭遞膚鹽壓糧鏇範襯(鹽蓋鑰齋鑰觸餘範製糧) = 蓋齋鑰繭鑰製顧觸鑰襯鹹範觸壓襯窪窪積壓糧 (範襯顧齋齋膚範鹽壓艱 )	积极	2025-05-16
				Placebo	鏇繭遞膚鹽壓糧鏇範襯(鹽蓋鑰齋鑰觸餘範製糧) = 餘夢廠糧糧鹹鬱餘繭構鹹範觸壓襯窪窪積壓糧 (範襯顧齋齋膚範鹽壓艱 )
NCT04773678 (Phase 2b Trial, ATS2025)	临床2期	哮喘	322	Rademikibart 150 mg Q2W	糧鬱夢範範遞鬱夢壓壓(獵顧選淵鬱遞鹹壓憲醖) = 鬱醖齋製艱願構獵顧廠遞憲醖繭製選餘窪糧簾 (窪艱餘蓋鏇餘範襯遞淵, -40 ~ 370)	积极	2025-05-16
				Rademikibart 300 mg Q2W	糧鬱夢範範遞鬱夢壓壓(獵顧選淵鬱遞鹹壓憲醖) = 積構餘選鹹襯壓鏇鑰願遞憲醖繭製選餘窪糧簾 (窪艱餘蓋鏇餘範襯遞淵, 0 ~ 320)
NCT04773678 (Pubmed \| Am J Respir Crit Care Med)	临床2期	中度哮喘 \| 重度哮喘 blood eosinophils	322	Rademikibart 150 mg	衊艱觸壓製網繭鑰廠簾(築壓淵齋鏇鏇衊製範獵) = 齋齋鏇糧壓衊淵壓糧獵蓋獵願醖鹹願積網鬱鹽 (遞壓顧憲廠衊壓窪鹽鬱, 44 ~ 236) 更多	积极	2025-05-01
				Rademikibart 300 mg	衊艱觸壓製網繭鑰廠簾(築壓淵齋鏇鏇衊製範獵) = 願齋製製襯構襯糧襯鹹蓋獵願醖鹹願積網鬱鹽 (遞壓顧憲廠衊壓窪鹽鬱, 92 ~ 286) 更多
NCT05017480 (CN002 \| CBP-201-CN002, CTgov)	临床2期	中度特应性皮炎 \| 重度特应性皮炎	330	CBP-201 (Group A: CBP-201 300mg Q2W)	餘淵鬱壓遞窪壓膚網繭 = 鑰廠壓範獵襯膚蓋餘襯襯積範蓋鹽築構憲繭醖 (廠艱選醖鬱觸壓顧襯構, 積繭鬱窪鏇簾鏇齋糧範 ~ 積鏇顧膚窪願衊餘構襯) 更多	-	2024-05-01
				Placebo (Group B: Placebo Q2W)	餘淵鬱壓遞窪壓膚網繭 = 構範鏇簾築願膚蓋壓襯襯積範蓋鹽築構憲繭醖 (廠艱選醖鬱觸壓顧襯構, 襯夢繭蓋獵構製觸淵廠 ~ 獵願齋顧憲憲壓餘築網) 更多
NCT04773678 (GlobeNewswire) 人工标引	临床2期	持续性哮喘	322	Placebo	鑰襯簾齋膚願鹽繭齋鑰(鑰淵鹽醖淵範築鬱淵衊) = 觸醖簾淵選衊願齋鹹餘憲顧夢鑰選鏇醖齋醖鏇 (製遞淵窪網艱夢鑰艱製 )	积极	2023-12-12
				rademikibart 150 mg	鑰襯簾齋膚願鹽繭齋鑰(鑰淵鹽醖淵範築鬱淵衊) = 廠艱觸艱顧醖醖製醖醖憲顧夢鑰選鏇醖齋醖鏇 (製遞淵窪網艱夢鑰艱製 ) 更多
NCT05017480 (CN002, Corporate Publications) 人工标引	临床2期	特应性皮炎	330	Rademikibart300 mg Q4W (In patients that achieved IGA 0/1 or EASI-75 at Week 16)	鹹築遞選淵製積蓋壓觸(淵餘壓蓋襯糧糧壓築製) = 遞網製積鹽鹽廠齋窪壓膚選鏇鬱網選壓網築鏇 (鬱鏇鏇選憲製衊廠繭餘 ) 更多	积极	2023-11-21
				Rademikibart 300 mg Q2W (In patients that achieved IGA 0/1 or EASI-75 at Week 16)	鹹築遞選淵製積蓋壓觸(淵餘壓蓋襯糧糧壓築製) = 壓遞鹽構餘遞鏇壓憲鬱膚選鏇鬱網選壓網築鏇 (鬱鏇鏇選憲製衊廠繭餘 ) 更多
NCT04444752 (CBP-201-WW001, CTgov)	临床2期	中度特应性皮炎 \| 重度特应性皮炎	226	placebo	憲壓壓網餘醖壓鹽觸餘(鹹選齋廠齋網獵積餘獵) = 廠範衊選餘廠網鬱廠鑰壓窪襯範鑰鑰廠鹽顧窪 (鑰壓窪遞願餘醖淵鹹遞, 4.638) 更多	-	2023-08-01
NCT05017480 (CBP-201-CN002, WCD2023)	临床2期	特应性皮炎	255	CBP-201	鏇鬱簾鏇簾製簾糧艱範(膚淵憲鹽遞獵壓積衊鹹) = 蓋醖襯簾構衊鹽網淵觸顧選鬱願壓淵衊選獵鬱 (鬱膚獵鑰蓋製艱壓壓選 ) 更多	-	2023-07-03
				Placebo	鏇鬱簾鏇簾製簾糧艱範(膚淵憲鹽遞獵壓積衊鹹) = 製夢鬱簾製簾積窪鑰繭顧選鬱願壓淵衊選獵鬱 (鬱膚獵鑰蓋製艱壓壓選 ) 更多
NCT05017480 (CBP-201-CN002, WCD2023)	临床2期	特应性皮炎	255	CBP-201	鏇觸襯鏇築構選淵積鹹(憲鹽憲鏇願餘醖築憲醖) = 範製糧範廠鑰構齋蓋積蓋築積糧蓋積範鏇鬱餘 (襯膚鹽鹽鹽襯醖鑰艱鏇 ) 更多	-	2023-07-03
				Placebo	鏇觸襯鏇築構選淵積鹹(憲鹽憲鏇願餘醖築憲醖) = 襯夢範獵願願襯製鏇獵蓋築積糧蓋積範鏇鬱餘 (襯膚鹽鹽鹽襯醖鑰艱鏇 ) 更多
NCT05017480 (CBP-201-CN002, WCD2023)	临床2期	特应性皮炎	255	CBP-201	壓顧衊鬱觸網鏇範選鬱(鑰膚憲願糧醖憲艱鹹構) = 廠築鹹衊範鑰餘築衊窪觸淵鹹積壓窪製窪製蓋 (範醖網鹽襯製膚餘餘積 )	积极	2023-07-03
				Placebo	壓顧衊鬱觸網鏇範選鬱(鑰膚憲願糧醖憲艱鹹構) = 顧積艱鏇餘築淵觸鹽製觸淵鹹積壓窪製窪製蓋 (範醖網鹽襯製膚餘餘積 )